KING OF PRUSSIA, Pa., June 25 /PRNewswire/ -- HighPoint Solutions LLC, a premier provider of business-driven IT solutions, announced today it has been selected to develop an Incentive Compensation Plan for a new Benign Prostatic Hyperplasia (BPH) product currently under FDA approval review. With the project's completion targeted for late summer 2008, the goal of the compensation plan is to motivate the field sales force and ensure the alignment of tactical activities with the product's strategic goals and budgets.
HighPoint Solutions has partnered with Qforma, the leader in advanced analytics and predictive modeling for pharmaceutical companies, on the initiative. Using a physician target universe built from Qforma's iQMap(TM), HighPoint Solutions will develop the incentive compensation plans for the launch product across all levels of the organization to drive the product's success.
"Our client is launching its new product in a crowded marketplace where the gold standard drug is going generic in 2010. It is crucial that a plan is developed offering the right balance of motivation for the sales team and realistic product uptake, while remaining within the product's budget," explained Chris Colapietro, vice president of Strategy and Marketing at HighPoint Solutions.
Alan Reicheg, Qforma's senior vice president of Commercial Operations, added, "Advances in analytics are revealing customer behaviors and emerging market shifts that point to opportunities, which can be measured and quantified in the BPH market. This type of precision targeting is now benchmark technology and our client will use it to make well-informed, strategic sales and marketing decisions."
This project combines HighPoint Solutions' industry expertise with
Qforma's advanced technologies, to uncover, interpret and utilize insights
from prescribing and customer peer interactions present in large data sets
-- ultimately increasing sales and marketing effectiveness whil
|SOURCE HighPoint Solutions LLC|
Copyright©2008 PR Newswire.
All rights reserved